# Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases

> **NIH NIH N01** · GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC · 2024 · $4,211,973

## Abstract

To support the development of promising diagnostics technologies for biothreat pathogens and toxins, as well as pathogens causing emerging and reemerging infectious diseases. Areas of support may focus on improving performance of agnostic nucleic acid sequencing solutions on commercial platforms; methods that improve protein analyte detection; and efforts to improve direct-from-blood or other biofluid detection and identification of microbial infection.

## Key facts

- **NIH application ID:** 11196801
- **Project number:** 75N93024C00051-0-9999-1
- **Recipient organization:** GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC
- **Principal Investigator:** RALF LENIGK
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $4,211,973
- **Award type:** —
- **Project period:** 2024-09-18 → 2029-09-17

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11196801

## Citation

> US National Institutes of Health, RePORTER application 11196801, Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases (75N93024C00051-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11196801. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*